Bradley Sadler, MD
Psychiatry · Mobile, ALNPI 1306983143
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,860 of the $123,674 with a category attached, or 67.8%. 29 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 48.5% of the total. 2025 is the largest year on record at $74,138, more than ten times the $1,501 reported in 2019. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 637 payments — averaging $194.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60K
- Johnson & Johnson$44K
- Supernus Pharmaceuticals, Inc.$12K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Neuronetics, Inc.$558
- plus $4K from 23 others
What the payments were for
- Consulting fees$5,5004%
- Speaking & faculty fees$83,86068%
- Travel & lodging$20,99017%
- Food & beverage$13,17111%
- Education$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 88 | $60,023 |
| Johnson & Johnson | 152 | $44,372 |
| Supernus Pharmaceuticals, Inc. | 32 | $11,557 |
| AbbVie(2 entities) | 147 | $1,770 |
| Teva Pharmaceuticals USA, Inc. | 45 | $1,643 |
| Neuronetics, Inc. | 6 | $558 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $546 |
| Sunovion Pharmaceuticals Inc. | 1 | $420 |
| Otsuka America Pharmaceutical, Inc. | 24 | $412 |
| Neurocrine Biosciences, Inc. | 11 | $372 |
| Lundbeck LLC | 17 | $329 |
| Alkermes, Inc. | 13 | $307 |
| Axsome Therapeutics, Inc. | 11 | $244 |
| Neos Therapeutics, LP | 12 | $232 |
| Vanda Pharmaceuticals Inc. | 7 | $199 |
| Indivior Inc. | 6 | $134 |
| Corium, LLC | 7 | $134 |
| Shire North American Group Inc | 5 | $87 |
| Eisai Inc. | 3 | $56 |
| Ironshore Pharmaceuticals Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Almatica Pharma LLC | 2 | $38 |
| Bioxcel Therapeutics, Inc. | 2 | $32 |
| Bausch Health US, LLC | 2 | $32 |
| Tris Pharma Inc | 1 | $23 |
| Orexo US, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$58,850
- SPRAVATO$41,811
- QELBREE$11,020
- AUSTEDO$622
- LATUDA$420
- NEUROSTAR TMS THERAPY SYSTEM$403
- Austedo XR$216
- INGREZZA$139
- NEUROSTAR TMS THERAPY$119
- TRINTELLIX$113
- VRAYLAR$101
How this compares
$123,674 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 318 | $443,992 |
| RexultiBrexpiprazole | 42 | $62,815 |
| VraylarCariprazine Hcl | 32 | $46,993 |
| TrintellixVortioxetine Hydrobromide | 51 | $31,347 |
| SublocadeBuprenorphine | 14 | $30,814 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 122 | $17,006 |
| Lurasidone Hcl | 59 | $14,647 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 23 | $13,533 |
| Aripiprazole | 141 | $6,835 |
| Vilazodone Hcl | 56 | $6,181 |
| Ziprasidone Hcl | 84 | $4,953 |
| Bupropion XlBupropion Hcl | 185 | $3,915 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 27 | $3,841 |
| Buspirone Hcl | 219 | $3,704 |
| Duloxetine Hcl | 118 | $3,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $44,372 | $443,992318 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $412 | $62,81542 claims |
| AbbVieVraylar | $1,770 | $46,99332 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $546 | $31,34751 claims |
| Indivior Inc.Sublocade | $134 | $30,81414 claims |
| Orexo US, Inc.Zubsolv | $14 | $13,53323 claims |
| Almatica Pharma LLCSertraline Hcl | $38 | $838108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Mobile
- Mark HaygoodMobile$348K
- Michael MarshallMobile$59K
- Mary Cohen ColsonMobile$10K
- Lucas BooneMobile$10K
- Bradley BrooksMobile$6K
- Sandra ParkerMobile$5K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.